Non-Hodgkin lymphoma (NHL) affects over 400,000 people in the United States; its incidence increases with age. Treatment options are numerous and expanding, yet efficacy is often limited by toxicity, particularly in the elderly. Nearly 70% patients eventually die of the disease. Many patients explore less toxic alternative therapeutics proposed to boost anti-tumor immunity, despite a paucity of...

objective: a number of studies have demonstrated the potential antitumor effects of saffron and its constituents on different malignant cells in vitro. it has been reported that a novel glycoconjugate isolated from corms and callus of saffron possesses cytotoxic activity against different tumor cellswith nitric oxide (no) production. these data suggest that the cytotoxic effect of saffron extra...

background: erythropoietin (epo) is a glycoprotein hormone function to regulate the production of red blood cells. deficiency of epo is known to cause anemia in chronically infected renal patients and they require regular blood transfusion. availability of recombinant epo has eliminated the need for blood transfusion and now it is extensively used for the treatment of anemia. glycosylation of e...

Mantle cell lymphoma (MCL) is an infrequent subtype of non-Hodgkin's lymphoma (NHL) and represents between 4-8% of adult lymphomas. Recently an increase in its incidence to 1-2 cases/100,000 inhabitants/year has been observed. The first line of treatment is based on chemoimmunotherapy and depends on age and the initial stage at diagnosis. There are no second line or successive treatments. There...

With an incidence rate of 15 per 100 000, non-Hodgkin’s lymphoma (NHL) accounts for the majority of lymphoid neoplasms in Europe [1]. Although in most of these entities the results of first-line therapy are becoming more and more effective, allogeneic stem cell transplantation (alloSCT) is increasingly used in NHL. Numbers of NHL allotransplants registered with the European Society for Blood an...

BACKGROUND Non-Hodgkin lymphoma (NHL) is a malignancy etiologically linked to immunomodulatory exposures and disorders. Endogenous female sex hormones may modify immune function and influence NHL risk. Few studies have examined associations between reproductive factors, which can serve as surrogates for such hormonal exposures, and NHL risk by subtype. METHODOLOGY/PRINCIPAL FINDINGS Women in ...

The 5th International Symposium on Childhood, Adolescent and Young Adult (CAYA) Non-Hodgkin Lymphoma (NHL) was held in Varese, Italy, from 21-25 October 2015. This review represents a summary of the scientific sessions of this international symposium including childhood, adolescent and young adult (AYA) NHL in countries with limited socio-economic resources, AYA NHL, anaplastic large cell lymph...

CD22 is a B-cell specific membrane glyco-protein that mediates homotypic and heterotypic celladhesion; it also regulates B-cell receptor (BCR)-mediatedsignals. Monoclonal antibodies (mAb) directed at theligand binding domain of CD22 initiate CD22-mediatedsignal transduction and apoptosis in B-cell lymphomas(NHL). Amino acid analysis of the complimentary deter-mining ...

Rituximab is the first line drug to treat non Hodgkin's lymphoma (B-NHL) alone or in combination with chemotherapy. However, 30-40% of B-NHL patients are unresponsive to rituximab or resistant after therapy. Human phosphatidylethanolamine-binding protein 4 (hPEBP4) is a novel member of PEBP family and functions as an anti-apoptotic molecule. In this study, we found hPEBP4 to be expressed in up ...

Extranodal natural killer cell (NK) T lymphoma (ENKL) is a rare type of non Hodgkins lymphoma, accounting for 5% 10% total NHL cases.